1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Akero First To Show Benefit In Cirrhotic NASH Patients

 
• By Joseph Haas

Although the data are from a small cohort of an ongoing study, Akero’s FGF21 analog reduces fibrosis score by at least one stage in 33% of cirrhotic NASH patients.

3D illustration of many arrows symbols pointing in the same direction and one arrow going back. Concept of regression.
In a small sample, Akero's EFX showed an ability to reverse cirrhosis in NASH patients

Akero Therapeutics, Inc.’s Phase II FGF21 analog efruxifermin (EFX/AKR-001) demonstrated the ability to reduce fibrosis score by one stage or more in non-alcoholic steatohepatitis patients with cirrhosis after just 16 weeks of treatment, becoming the first NASH candidate to show a benefit in cirrhotic patients. The biotech noted on 22 March that the data derived from a 30-patient cohort of a Phase IIa study that was not powered to show statistical significance on histologic endpoints, but analysts called the data potentially groundbreaking all the same.

Previously, the South San Francisco-based company had shown that EFX could reduce hepatic fat by 63%-72% in NASH patients with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Genmab/AbbVie’s Epkinly Likely To See Label Expansion After Phase III Win

 
• By Alaric DeArment

The FDA is expected to rule on the anti-CD20xCD3 bispecific combined with rituximab/lenalidomide in second-line follicular lymphoma in November.

Novartis’s ‘Pipeline-In-A-Product’ Assets Progressing Well

 
• By Kevin Grogan

CMO Shreeram Aradhye talks to Scrip about the promise shown by ianalumab, remibrutinib and a next-generation CAR-T for immunological disorders.

Vertex’s Pain Drug Failure Adds To Investor Doubts

 
• By Andrew McConaghie

A Phase II trial to develop a second NaV1.8 pain signal inhibitor for acute pain has failed and the US FDA has given a thumbs down on Journavx’s path to broader use in peripheral neuropathic pain.

Cardiff Pushes Towards Colorectal Cancer Phase III As Funding Questions Loom

 
• By Manas Mishra

Cardiff Oncology is open to going it alone, a partnership and even an exit as the San Diego, CA-based firm tries to push its PLK1 inhibitor through late-stage development.

More from R&D

Aurigene Oncology CEO On Biotech Valuations, CAR-Ts And Reimbursement Models

 
• By Anju Ghangurde

Aurigene Oncology CEO talks in this audio interview about the tough biotech funding environment, pipeline assets including a CAR-T therapy in Phase II, "hybrid" manufacturing, outcome-based reimbursement and the promise of bispecifics and multispecifics, including Akeso's PD-1/VEGF bispecific.

Allogene Sticks With Standard Lymphodepletion In CAR-T Trial After Patient Death

 
• By Alaric DeArment

The company said it will no longer use ALLO-647 after a patient developed a fatal adenovirus infection, and it will pursue further development of its Dagger technology to minimize or eliminate the need for lymphodepletion.

BioNTech Outlines Development Plan For PD-L1xVEGF-Targeting BNT-327

 
• By Jessica Merrill

The company, with partner Bristol Myers Squibb, has a three-wave development strategy for BNT-327: “establish, combine, broaden.”